ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,288Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 656

$1.28M Total Retail Price of All Prescriptions

Rank: 22 out of 656

767 Patients Receiving at Least One Drug in Part D
20%Patients 65 Years and Older
88% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 767 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

2% of this provider’s 767 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

5% of this provider’s 1,581 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$124 was the average price of a prescription from this provider, compared to $147 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
RISPERIDONE 645 56 1 2
DIVALPROEX SODIUM ER 453 81 2 10
ZOLPIDEM TARTRATE 416 60 3 3
ABILIFY 412 33 4 6
QUETIAPINE FUMARATE 402 51 5 5
TRAZODONE HCL 387 59 6 1
CITALOPRAM HBR 376 80 7 9
SERTRALINE HCL 368 50 8 8
CYMBALTA 350 47 9 7
BENZTROPINE MESYLATE 282 38 R 10 4
VENLAFAXINE HCL ER 267 58 11 15
MIRTAZAPINE 266 67 12 13
ZIPRASIDONE HCL 261 30 13 27
FLUOXETINE HCL 245 45 14 11
OLANZAPINE 233 23 15 12
BUPROPION XL 200 27 16 17
SEROQUEL 194 20 17 20
LAMOTRIGINE 190 29 18 14
HYDROXYZINE HCL 186 17 R 19 43
FLUVOXAMINE MALEATE 173 21 20 63
PAROXETINE HCL 159 23 21 23
GABAPENTIN 152 0 22 29
TOPIRAMATE 144 19 23 34
BUPROPION HCL SR 126 0 24 25
BUSPIRONE HCL 122 42 25 19
ESCITALOPRAM OXALATE 117 28 26 18
HALOPERIDOL 112 19 27 26
HYDROXYZINE PAMOATE 109 12 R 28 32
OXCARBAZEPINE 107 0 29 28
LEVOTHYROXINE SODIUM 100 24 30 50
INVEGA 97 0 31 38
GEODON 97 23 31 57
AMITRIPTYLINE HCL 88 12 R 33 42
PERPHENAZINE 87 0 34 48
DOXEPIN HCL 84 16 35 41
AMPHETAMINE SALT COMBO 81 0 S2 36 37
LITHIUM CARBONATE 78 17 37 16
OMEPRAZOLE 78 14 37 73
PRISTIQ ER 71 14 39 30
DIVALPROEX SODIUM 67 11 40 24
METHYLPHENIDATE HCL 67 28 40 56
CARBAMAZEPINE 65 0 42 35
ROPINIROLE HCL 59 14 43 98
LUNESTA 58 12 44 51
BUPROPION HCL 53 11 45 75
LISINOPRIL 52 0 46 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 2, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.